Theravance Biopharma, Inc.

NasdaqGM:TBPH 주식 보고서

시가총액: US$465.7m

Theravance Biopharma 관리

관리 기준 확인 3/4

Theravance Biopharma CEO는 Rick Winningham, Jun2014 에 임명되었습니다 의 임기는 10.42 년입니다. 총 연간 보상은 $ 4.32M, 24.3% 로 구성됩니다. 24.3% 급여 및 75.7% 보너스(회사 주식 및 옵션 포함). 는 $ 18.06M 가치에 해당하는 회사 주식의 3.88% 직접 소유합니다. 18.06M. 경영진과 이사회의 평균 재임 기간은 각각 2.4 년과 6.8 년입니다.

주요 정보

Rick Winningham

최고 경영자

US$4.3m

총 보상

CEO 급여 비율24.3%
CEO 임기10.4yrs
CEO 소유권3.9%
경영진 평균 재임 기간2.4yrs
이사회 평균 재임 기간6.8yrs

최근 관리 업데이트

Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now

May 02
Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now

Recent updates

With Theravance Biopharma, Inc. (NASDAQ:TBPH) It Looks Like You'll Get What You Pay For

Nov 12
With Theravance Biopharma, Inc. (NASDAQ:TBPH) It Looks Like You'll Get What You Pay For

We're Interested To See How Theravance Biopharma (NASDAQ:TBPH) Uses Its Cash Hoard To Grow

Jul 16
We're Interested To See How Theravance Biopharma (NASDAQ:TBPH) Uses Its Cash Hoard To Grow

Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now

May 02
Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now

Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S

Feb 05
Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S

Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts

Nov 11
Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts

Theravance to purchase $95M of ordinary shares

Sep 28

Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade

Sep 21
Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade

Theravance Biopharma announces $250M capital return program

Sep 19

Theravance Biopharma GAAP EPS of -$0.11, revenue of $11.1M

Aug 04

Theravance: All-Round Failure

Mar 10

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%

Aug 09
Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%

Theravance Bio stock falls 6% after nezulcitinib flunks mid-stage COVID-19 induced lung injury study

Jun 21

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year

May 09
Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year

CEO 보상 분석

Rick Winningham 의 보수는 Theravance Biopharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$49m

Jun 30 2024n/an/a

-US$46m

Mar 31 2024n/an/a

-US$45m

Dec 31 2023US$4mUS$1m

-US$55m

Sep 30 2023n/an/a

-US$61m

Jun 30 2023n/an/a

-US$68m

Mar 31 2023n/an/a

-US$75m

Dec 31 2022US$6mUS$1m

-US$93m

Sep 30 2022n/an/a

-US$136m

Jun 30 2022n/an/a

-US$196m

Mar 31 2022n/an/a

-US$226m

Dec 31 2021US$4mUS$1m

-US$265m

Sep 30 2021n/an/a

-US$266m

Jun 30 2021n/an/a

-US$264m

Mar 31 2021n/an/a

-US$275m

Dec 31 2020US$7mUS$1m

-US$295m

Sep 30 2020n/an/a

-US$285m

Jun 30 2020n/an/a

-US$270m

Mar 31 2020n/an/a

-US$247m

Dec 31 2019US$6mUS$984k

-US$236m

Sep 30 2019n/an/a

-US$221m

Jun 30 2019n/an/a

-US$222m

Mar 31 2019n/an/a

-US$223m

Dec 31 2018US$3mUS$957k

-US$216m

Sep 30 2018n/an/a

-US$252m

Jun 30 2018n/an/a

-US$260m

Mar 31 2018n/an/a

-US$285m

Dec 31 2017US$2mUS$933k

-US$285m

보상 대 시장: Rick 의 총 보상 ($USD 4.32M )은 US 시장( $USD 2.22M ).

보상과 수익: Rick 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.


CEO

Rick Winningham (64 yo)

10.4yrs

테뉴어

US$4,318,531

보상

Mr. Rick E. Winningham, M.B.A., served as Chairman of Retrotope Inc. since February 2021 until January 2022. He serves as Director at Rivus Pharmaceuticals, Inc. since 2024. He has been Lead Independent Di...


리더십 팀

이름위치테뉴어보상소유권
Rick Winningham
CEO & Director10.4yrsUS$4.32m3.88%
$ 18.1m
Aziz Sawaf
Senior VP & CFO1.8yrsUS$1.39m0.64%
$ 3.0m
Stuart Knight
Senior VP of IT&I and Chief Information Officerno data데이터 없음데이터 없음
Gail Cohen
Vice President of Corporate Communications & Investor Relationsno data데이터 없음데이터 없음
Brett Grimaud
Senior VP2.4yrs데이터 없음0.68%
$ 3.2m
Rhonda Farnum
Chief Business Officer and Senior VP of Commercial & Medical Affairs2.9yrsUS$942.81k0.64%
$ 3.0m
Stacy Pryce
Senior VP & Chief Strategy Officer2.2yrs데이터 없음데이터 없음
Aine Miller
SVP of Dev.no data데이터 없음0.31%
$ 1.4m

2.4yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 관리: TBPH 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
Rick Winningham
CEO & Director11.3yrsUS$4.32m3.88%
$ 18.1m
Eran Broshy
Independent Director10.4yrsUS$205.14k0.14%
$ 663.1k
Deepika Pakianathan
Independent Director4.3yrsUS$207.68k0.096%
$ 449.0k
Dean Mitchell
Lead Independent Director10.4yrsUS$211.73k0.16%
$ 762.9k
James Kelly
Independent Director1.6yrsUS$43.10k데이터 없음
Donal O'Connor
Independent Director9.1yrsUS$195.80k0.13%
$ 601.8k
Susannah Gray
Independent Chairman1.8yrsUS$346.47k0.064%
$ 298.2k
Laurie Smaldone Alsup
Independent Director6.8yrsUS$197.68k0.13%
$ 609.2k
Jeremy Grant
Independent Directorless than a yearUS$168.36k0.045%
$ 211.2k

6.8yrs

평균 재임 기간

64.5yo

평균 연령

경험이 풍부한 이사회: TBPH 의 이사회경험(평균 재직 기간 6.8 년)으로 간주됩니다.